97 related articles for article (PubMed ID: 38444005)
1. Epithelial ovarian cancer and brain metastases: might the
Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
[TBL] [Abstract][Full Text] [Related]
2. Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?
Turinetto M; Ray-Coquard I; Gourley C
ESMO Open; 2024 May; 9(5):102983. PubMed ID: 38663167
[No Abstract] [Full Text] [Related]
3. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
[TBL] [Abstract][Full Text] [Related]
4. Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT).
Kobayashi Y; Shimada M; Tamate M; Cho HW; Zhu J; Chou HH; Kajiyama H; Okamoto A; Aoki D; Kang S; Lee JW; Kim JW; Kim JH; Lin Z; Liu J; Wu X; Lai HC; Chang TC; Lai CH; Kim YM; Enomoto T
J Gynecol Oncol; 2024 May; 35(3):e87. PubMed ID: 38606827
[TBL] [Abstract][Full Text] [Related]
5. Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer.
Uekusa R; Yokoi A; Watanabe E; Yoshida K; Yoshihara M; Tamauchi S; Shimizu Y; Ikeda Y; Yoshikawa N; Niimi K; Suzuki S; Kajiyama H
Sci Rep; 2024 Jun; 14(1):12595. PubMed ID: 38824213
[TBL] [Abstract][Full Text] [Related]
6. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
7. Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review.
Alemzadeh E; Allahqoli L; Mazidimoradi A; Alemzadeh E; Ghasemi F; Salehiniya H; Alkatout I
Oncol Res; 2024; 32(5):831-847. PubMed ID: 38686048
[TBL] [Abstract][Full Text] [Related]
8. Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.
De Lazzari G; Opattova A; Arena S
J Exp Clin Cancer Res; 2024 May; 43(1):146. PubMed ID: 38750579
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics, treatment patterns, and outcomes in adult patients with germline
Obeid E; Parikh RC; Esterberg E; Arondekar B; Hitchens A; Arruda LS; Niyazov A; Whitaker K
Front Oncol; 2024; 14():1341665. PubMed ID: 38817906
[TBL] [Abstract][Full Text] [Related]
10. Progesterone Enhances Niraparib Efficacy in Ovarian Cancer by Promoting Palmitoleic-Acid-Mediated Ferroptosis.
Wu N; Zhang X; Fang C; Zhu M; Wang Z; Jian L; Tan W; Wang Y; Li H; Xu X; Zhou Y; Chu TY; Wang J; Liao Q
Research (Wash D C); 2024; 7():0371. PubMed ID: 38798714
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi).
Durante S; Cuccia F; Rigo M; Caminiti G; Mastroleo F; Lazzari R; Corrao G; Caruso G; Vigorito S; Cattani F; Ferrera G; Chiantera V; Alongi F; Colombo N; Jereczek-Fossa BA
Int J Gynecol Cancer; 2024 May; ():. PubMed ID: 38821546
[TBL] [Abstract][Full Text] [Related]
12.
Mayor P; Gay LM; Lele S; Elvin JA
Gynecol Oncol Rep; 2017 Aug; 21():57-60. PubMed ID: 28706968
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
[TBL] [
